ESC-CHF: Guidelines for the aspirational and the practical

Heart

Volumn 92, Issue 4, 2006, Pages 437-440

  Brady, Adrian J B ^a   Poole Wilson, P A ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM SENSITIZER; CANDESARTAN; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDRALAZINE; INOTROPIC AGENT; ISOSORBIDE DINITRATE; LEVOSIMENDAN; LOOP DIURETIC AGENT; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; PERINDOPRIL; SPIRONOLACTONE; STATINE DERIVATIVE; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT;

ALGORITHM; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGY; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DEFIBRILLATOR; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; EDITORIAL; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; MEDICAL SOCIETY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL;

CARDIOVASCULAR AGENTS; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE, CONGESTIVE; HUMANS; PRACTICE GUIDELINES; SOCIETIES, MEDICAL;

EID: 33645213894     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.083980     Document Type: Editorial

References (21)

1. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure (update 2005). Eur Heart J 2005;26:1115-41.
2. NICE. Chronic heart failure. Management of chronic heart failure in adults in primary and secondary care. National Institute for Clinical Excellence July, 2003.
3. Scottish Intercollegiate Guidelines Network. Diagnosis and treatment of heart failure due to left ventricular systolic dysfunction. Scottish Intercollegiate Guidelines Network 1999;(SIGN).
4. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
5. The Capricorn Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
6. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.
7. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomised controlled trial, Lancet 2003;362:7-13.
8. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
9. Fox KM. European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
10. Flather MD, Shibata MC, Coats AJ, et al for the SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25.
11. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
12. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-59.
13. Dahlof B, Sever PS, Poulter NR, et al. Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906.
14. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-17.
15. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543-51.
16. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
17. Cohn JN, Archibald DG, Phil M, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperation study. N Engl J Med 1986;314:1547-52.
18. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
19. Cleland J, Findlay I, Jafri S, et al. The warfarin/aspirin study in heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157-64.
20. Cleland JG, Daubert JC, Erdmann E, et al for the Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
21. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.